López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539]
Corresponding Author of This Article
Dr. Pilar López-Serrano, Department of Gastroenterology, University Hospital Fundación Alcorcón, Calle Budapest 1, 28922 Madrid, Spain. pilarlopezserrano@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Mar 27, 2015; 7(3): 539-547 Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.539
Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy
Pilar López-Serrano, Elsa de la Fuente Briongos, Elisa Carrera Alonso, Jose Lázaro Pérez-Calle, Conrado Fernández Rodríguez
Pilar López-Serrano, Elsa de la Fuente Briongos, Jose Lázaro Pérez-Calle, Conrado Fernández Rodríguez, Department of Gastroenterology, University Hospital Fundación Alcorcón, 28922 Madrid, Spain
Elisa Carrera Alonso, Department of Gastroenterology, University Hospital of Guadalajara, 19002 Guadalajara, Spain
Author contributions: López-Serrano P, de la Fuente Briongos E, Carrera Alonso E, Pérez-Calle JL and Fernandez Rodríguez C contributed equally to this work; all authors had approved the final version of the manuscript.
Conflict-of-interest: Dr. Conrado Fernández Rodríguez is a advisory board member, panel reviewer and consultant for Bristol Myers Squibb. The rest of the authors whose names are listed certify that they have NO affiliations or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Pilar López-Serrano, Department of Gastroenterology, University Hospital Fundación Alcorcón, Calle Budapest 1, 28922 Madrid, Spain. pilarlopezserrano@gmail.com
Telephone: +34-91-6219400 Fax: +34-91-6219890
Received: August 28, 2014 Peer-review started: August 30, 2014 First decision: November 14, 2014 Revised: December 28, 2014 Accepted: January 9, 2015 Article in press: January 9, 2015 Published online: March 27, 2015
Core Tip
Core tip: Few reviews have been published including data of the three more common inflammatory diseases that require immunosuppressive therapy: inflammatory bowel disease, rheumatic and dermatologic diseases. This paper is focused on the risk of reactivation of hepatitis B virus under immunosuppressants, and particularly corticosteroids. Although most of the guidelines do not specify the necessity of prophylaxis in case of monotherapy with corticosteroids, the specialists responsible of these patients are usually concerned about this issue. Moreover, the risk with low systemic bioavailability new corticosteroids has not been evaluated in previous reviews. This work summarizes the evidence of VHB reactivation in patients with inflammatory diseases: when and how to apply prophylaxis, with a special focus on “new” and “old” steroids.
